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Two Distinct Pathways for Histamine H2 Receptor Down-regulation
H2 LEU
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ACTION OF H2 AGONISTS*
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Pretreatment of Chinese hamster ovary cells express-
ing the histamine H2 receptor (CHOrH2 cells) with his-
tamine resulted in a time-dependent (t1⁄2 ' 7 h) and dose-
dependent (EC50 5 18 nM) H2 receptor down-regulation
measured as [125I]iodoaminopotentidine binding (44 6
10% down-regulation). Pretreatment of CHOrH2 cells
with cholera toxin or forskolin also led to H2 receptor
down-regulation. Forskolin time-dependently (t1⁄2 ' 7 h)
and dose-dependently (EC50 5 0.3 mM) induced H2 recep-
tor down-regulation. Both histamine and forskolin in-
duced rapid down-regulation of H2 receptor mRNA lev-
els, probably caused by mRNA destabilization.
Recently, Moro et al. (Moro, O., Lameh, J., Hogger, P.,
and Sade´e, W. (1993) J. Biol. Chem. 268, 22273–22276)
showed that hydrophobic amino acids in a conserved
G-protein-coupled receptor motif in the second intracel-
lular loop are implicated in G-protein coupling. To un-
couple the H2 receptor from the Gs-protein, we intro-
duced the Leu124 3 Ala mutation in the second
intracellular loop of the H2 receptor. The H2 Leu
124 3
Ala mutant showed altered agonist-binding parameters,
attenuated histamine-induced cAMP production, and
was down-regulated by concentrations of histamine that
did not give rise to cAMP production. Taken together, in
CHOrH2 cells, H2 receptor down-regulation appears to
be induced by two distinct pathways, a cAMP-dependent
and cAMP-independent pathway.
The introduction of molecular biology in the field of hista-
mine receptor research has greatly improved the possibilities to
study molecular aspects of histamine receptor proteins. In
1991, Gantz et al. (1) cloned the cDNA encoding the canine
histamine H2 receptor, which was followed by the cloning of
both the rat and human homologues (2, 3). The deduced amino
acid sequence of the H2 receptor proteins reveals the existence
of seven putative transmembrane domains, indicating that this
receptor is a member of the large family of G-protein-coupled
receptors (GPCR).1 This family of receptors is known to be
readily subjected to regulatory processes in order to control
receptor signaling and thus cellular communication (4). Short-
term exposure of receptors to high concentrations of agonists is
often followed by a decrease in cellular responsiveness, called
desensitization (5). Long-term exposure, on the other hand,
results in the reduction of receptor number (6) and is referred
to as receptor down-regulation. Since the histamine H2 recep-
tor is a member of this family of GPCRs, it is not surprising
that this receptor is also susceptible to such regulatory
mechanisms.
Recently, we have shown that in human U937 cells the
endogenously expressed histamine H2 receptors are indeed
rapidly desensitized when exposed to histamine (7). Similar
observations have been reported in other cellular systems (8,
9). Yet, so far, no detailed information is available on long-term
desensitization of the histamine H2 receptor such as receptor
down-regulation. Such processes may become apparent under
several pathophysiological conditions (e.g. asthmatic attack or
allergic reactions in general), during which histamine is re-
leased in large quantities, but might also occur under normal
physiological conditions. Recently, Diaz et al. (10) suggested for
example that in vivo receptor down-regulation might explain
the inverse relationship between H2 receptor expression and
the localization of histamine-synthesizing cells in the rodent
gastric wall. The regulation of H2 receptor expression has
gained further interest due to the potential therapeutic appli-
cation of H2 receptor agonists in patients suffering from con-
gestive heart failure (11).
Investigation of the regulation of H2 receptor expression has
so far been hampered by the availability of suitable model
systems. Cellular systems (7–9, 12) have been used to investi-
gate second messenger responses coupled to the histamine H2
receptor stimulation, but the used systems such as U937 cells
for example do not express a sufficiently high density of H2
receptors to permit radioligand binding studies, which are es-
sential for the investigation of long-term regulatory mecha-
nisms (7). Following the recent cloning of cDNAs or genes
encoding histamine H2 receptors, cell lines expressing consid-
erable amounts of histamine H2 receptors can be obtained (13,
14). Additionally, the availability of the H2 receptor gene allows
the construction of receptor mutants, which can provide mech-
anistic insights in phenomena like receptor down-regulation.
In the present study we have examined the effects of long-
term exposure of the rat histamine H2 receptor stably ex-
pressed in Chinese hamster ovary (CHO) cells (referred to as
CHOrH2 cells) (13) to H2 agonists and cAMP mobilizing agents
with regard to H2 receptor protein expression and H2 receptor
mRNA levels. In order to get more insight into the mechanisms
underlying H2 receptor regulation, we constructed a H2 recep-
tor mutant, in which leucine 124 in the second intracellular
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loop was substituted by an alanine. This H2 Leu
124 3 Ala
receptor mutant was partially uncoupled from its G-protein
and proved to be a suitable tool for investigating the existence
of possible cAMP-dependent and independent pathways in the
process of agonist-induced H2 receptor down-regulation.
MATERIALS AND METHODS
Cell Culture—CHO cells expressing the rat histamine H2 receptor
(CHOrH2) (13) and the mutated H2 Leu
124 3 Ala receptor
(CHOrH2Leu
124Ala) were grown at 37 °C in a humidified atmosphere
with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM), contain-
ing 10% (v/v) dialyzed fetal calf serum supplemented with 2 mM L-
glutamine, MEM amino acids, 50 IU/ml penicillin, and 50 mg/ml
streptomycin.
Site-directed Mutagenesis—The H2 receptor mutant, in which leucine
124 was substituted by alanine (Leu1243 Ala) (Fig. 7), was constructed
by means of the polymerase chain reaction. The oligonucleotides S1
(59-GGGAAGCTTGGCCCCAGAATGGAGCCCAATGGCACAGT), cor-
responding to nucleotides 29 to 21 (2) and a HindIII site (underlined),
and AS1 (59-GGGGGTACCGCGCTGGGTCCGTGACAGCGCAGTAG-
TTGTTCAAGCTGATCAT), corresponding to nucleotides 358 to 383 of
the complementary strand (2) containing a KpnI site (underlined) with
two nucleotide changes, were synthesized on an Applied Biosystems
DNA synthesizer (model 381A). Using 100 ng of pSVrH2 (13) as a
template, 0.4 mM S1, 0.4 mM AS2, 40 mM dNTPs, and 2.5 units of
Amplitaq according to the manufacturer’s protocol (Perkin Elmer), a
392-base pair DNA fragment of the H2 Leu
124 3 Ala receptor mutant
was amplified in 100 ml using 30 cycles at 94 °C for 1 min, 56 °C for 1
min, and 72 °C for 1.5 min and a final extension at 72 °C for 10 min. The
obtained PCR product was gel-purified and restricted with HindIII/
KpnI (Boehringer). This fragment was cloned into the plasmid pSP73
(Promega) containing the wild-type rH2 receptor, which was restricted
with KpnI and HindIII. Thereafter, the PCR-amplified sequence was
verified using the dideoxy chain termination method with the Seque-
nase kit (U. S. Biochemical Corp.). Subsequently, the coding sequence of
the mutated H2 Leu
124 3 Ala receptor was subcloned into the eukary-
otic pSV expression vector. CHO cells, deficient in dihydrofolate reduc-
tase, were stably transfected with 15 mg of pSVrH2Leu
124Ala using
Transfectam (Promega).
Membrane Preparation—CHOrH2 and CHOrH2Leu
124Ala cells were
washed three times with cold phosphate-buffered saline (137 mM NaCl,
2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4) and harvested with a
cell scraper and recovered by a 10-min centrifugation at 500 3 g. Cells
were homogenized in ice-cold 50 mM Na2/potassium phosphate buffer
(pH 7.4) with a Polytron homogenizer (5 s, maximal speed) and used for
radioligand binding studies. Protein concentrations were determined
according to Bradford using bovine serum albumin as a standard (15).
Histamine H2 Receptor Binding—The radiolabeled H2 receptor an-
tagonist [125I]iodoaminopotentidine ([125I]APT) was synthesized as de-
scribed previously (14). Triplicate assays were performed in polyethyl-
ene tubes in 50 mM Na2/potassium phosphate buffer containing gelatin
(0.1%) to prevent adsorption of the radioligand. In saturation studies,
increasing concentrations of [125I]APT were incubated with 5–10 mg of
membrane proteins in the absence or presence of 1 mM tiotidine in a
total volume of 400 ml. After 90 min at 30 °C, the incubations were
stopped by rapid dilution with 3 ml of ice-cold 20 mM Na2/potassium
phosphate buffer (pH 7.4) supplemented with 0.1% bovine serum albu-
min. The bound radioactivity was subsequently separated by filtration
with a Brandel cell harvester (Semat) through Whatman GF/B glass
fiber filters that had been treated with 0.3% polyethyleneimine. Filters
were washed twice with 3 ml of buffer, and radioactivity retained on the
filters was counted with a LKB-g-counter at an efficiency of 63%. The
binding data were evaluated by use of LIGAND, a nonlinear, weighted,
least squares curve-fitting procedure (16). Changes in H2 receptor den-
sity were denoted as a percentage down-regulation compared to non-
treated control cells. During the 24-h incubation of cells with various
histamine ligands or other compounds, cells were maintained in me-
dium without fetal calf serum.
Cyclic AMP Production—CHOrH2 and CHOrH2Leu
124Ala cells were
seeded in 24-well plates and cultured overnight in culture medium.
Cells were washed twice with DMEM, supplemented with 50 mM
HEPES (pH 7.4 at 37 °C), and preincubated for 30 min at 37 °C. There-
after, the medium was aspirated, appropriate drugs in DMEM/HEPES
supplemented with 300 mM phosphodiesterase inhibitor isobutylmeth-
ylxanthine (IBMX) were added, and the cells were incubated for 10 min
at 37 °C. The reaction was stopped by the rapid aspiration of the culture
medium and the addition of 200 ml of 0.1 N cold HCl. The cells were kept
on ice and disrupted by sonification (5 s, 50 watts, Labsonic 1510,
Braun-Melsungen). The resulting homogenate was frozen at 220 °C or
directly neutralized with 1 N NaOH and assayed for the presence of
cAMP. In order to determine the long-term effects of histamine treat-
ment on H2 receptor signaling, CHOrH2 cells were preincubated with
100 mM histamine for 24 h in DMEM without fetal calf serum. There-
after, these cells were thoroughly washed and preincubated for 1 h in
DMEM/HEPES at 37 °C before actual incubation with the indicated
drugs.
Cyclic AMP Assay—The amount of cAMP in the CHOrH2 and
CHOrH2Leu
124Ala cells was determined according to Nordstedt and
Fredholm (17), with some minor modifications. Briefly, a protein kinase
A-containing fraction was isolated from bovine adrenal glands. Adrenal
cortex was homogenized in 10 volumes of 100 mM Tris-HCl, 250 mM
NaCl, 10 mM EDTA, 0.25 M sucrose, and 0.1% 2-mercaptoethanol (pH
7.4 at 4 °C, buffer A) using an Omni-Sorval mixer (30 s, maximal speed)
and a Polytron homogenizer (10 s, maximal speed). The homogenate
was centrifuged for 60 min at 30,000 3 g at 4 °C. The supernatant,
containing protein kinase A, was carefully recovered and frozen in 1 ml
aliquots at 280 °C. Before use, the binding protein was diluted 5-fold in
ice-cold buffer A without sucrose and 2-mercaptoethanol and kept on
ice. Subsequently, 200 ml of the binding protein was mixed with 50–100
ml of the CHO homogenate or cAMP standards and 30,000 dpm of
[3H]cAMP. After incubation for 150 min at 4 °C, the mixture was
rapidly diluted with 3 ml of ice-cold 50 mM Tris-HCl (pH 7.4 at 4 °C) and
filtered through Whatman GF/B filters using a Brandel cell-harvester
(Semat). The radioactivity retained on the filters was measured by
liquid scintillation counting.
RNA Slot Blot Analysis—RNA was analyzed by means of mRNA slot
blot assay as described by Zhang et al. (18), with minor modifications.
Briefly, RNA was isolated according to the method of Chomczynski and
Sacchi (19), using Trizol reagent® (Life Technologies, Inc.), and RNA
was slot-blotted on a nitrocellulose filter (GeneScreen Plus, DuPont
NEN) and prehybridized for 2 h at 65 °C in 7% SDS, 0.5 M Na2HPO4, 1
mM EDTA (pH 7.2). Thereafter, filters were hybridized overnight with
a radioactive labeled 48-mer antisense rat H2 receptor oligonucleotide
(59-GATGGTGGCTGCCTTCCAGGAGCTGATGTGGTTGATCCGTT-
TGGCCTG-39, corresponding to nucleotides 631 to 678) or antisense rat
b-actin oligonucleotide (59-CTCCTGCTTGCTGATCCACATCTGCTGG-
AAGGTGGACAGTGAGGCCAG-39, corresponding to nucleotides 3040
to 3087) at 65 °C in 7% SDS, 0.5 M Na2PO4, and 1 mM EDTA (pH 7.2).
The rat H2 receptor oligonucleotide (1.5 pmol) was
32P-labeled by 39-end
tailing using 16 pmol of [a-32P]dATP (3000 Ci/mmol; Amersham) and 1
unit of terminal deoxynucleotidyltransferase (Boehringer) for 20 min at
37 °C. The b-actin oligonucleotide (5 pmol) was labeled using 10 pmol of
[g-32P]dATP (3000 Ci/mmol; Amersham) and 4 units of polynucleotide
kinase (Boehringer) for 30 min at 37 °C. The blots were washed twice
for 5 min at room temperature in 2 3 SSC (0.3 M NaCl, 0.03 M
Na3C6H5O7z2H2O) supplemented with 0.1% SDS, which was followed
by two 45-min washes at 65 °C with 2 3 SSC supplemented with 0.1%
SDS. The blots were exposed to a PhosphorScreen (Molecular Dynam-
ics) and signals were quantified with a PhosphorImager 425 (Molecular
Dynamics) using the computer program ImageQuant (Molecular Dy-
namics). H2 receptor mRNA levels were expressed as the ratio of the
values of the H2 receptor mRNA signals and the corresponding b-actin
signals.
Analysis of H2 Receptor mRNA Stability—H2 receptor mRNA levels
were determined after incubation of the CHOrH2 cells with actinomycin
D to block transcription as described previously (20). Cells were prein-
cubated with or without 100 mM histamine or with 10 mM forskolin for 1
h in DMEM. Thereafter, actinomycin D (10 mg/ml) was added. Cells
were harvested from 0 to 90 min after addition of actinomycin D. Total
RNA was extracted at each time point, and H2 receptor mRNA was
quantified by means of the mRNA slot blot assay as described above.
Chemicals—Histamine dihydrochloride, isobutylmethylxanthine
(IBMX), cyclic AMP (cAMP), forskolin, 1,9-dideoxyforskolin, cholera
toxin, and GTPgS were obtained from Sigma. Actinomycin D was pur-
chased from Boehringer Mannheim. [2,8-3H]cAMP (40 Ci/mmol) was
obtained from Amersham. H-89 dihydrochloride and KT5720 were pur-
chased from Calbiochem. Dimaprit dihydrobromide, homo- and nordi-
maprit dihydrochloride, amthamine dihydrobromide, amselamine dihy-
drobromide, and aminopotentidine were taken from laboratory stock.
Gifts of cimetidine (SmithKline Beecham), ranitidine dihydrochloride
(Glaxo), tiotidine (Imperial Chemical Industries), CHO cells expressing
the rat H2 receptor, and pSVrH2 vector (Dr. J.-C. Schwartz) are grate-
fully acknowledged.
Statistical Analysis—All data shown are expressed as mean 6 S.E. of
at least three independent experiments. Statistical analysis was carried
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out by Student’s t-test. p values , 0.05 were considered to indicate a
significant difference.
RESULTS
Histamine-induced H2 Receptor Down-regulation—Exposure
of CHOrH2 cells (13) to 100 mM histamine for prolonged periods
of time resulted in a time-dependent decrease of [125I]APT
binding (Fig. 1A). Maximum reduction of [125I]APT binding
was observed after a 16-h incubation of cells with 100 mM
histamine. Under this condition, histamine induced 44 6 10%
(p , 0.05) reduction of [125I]APT binding. Half-maximum re-
duction of the [125I]APT binding was recorded at an incubation
period of approximately 7 h. A 24-h incubation of CHOrH2 cells
with increasing concentrations of histamine led to a dose-de-
pendent reduction of [125I]APT binding (EC50 value 5 18 6 6
nM, mean 6 S.E., n 5 7) (Fig. 1B). The observed reduction of
[125I]APT binding was not reflected by a change in affinity of
[125I]APT for the H2 receptor, as its dissociation constant (Kd),
determined by means of saturation studies, remained unaf-
fected in CHOrH2 cells incubated with 100 mM histamine for 24
h (Table I). Exposure of CHOrH2 cells to histamine resulted
only in a marked decrease of the total number of [125I]APT
binding sites (Bmax) (Table I).
The recently described selective H2 receptor agonists amsel-
amine and amthamine (21, 22) induced cAMP production in
CHOrH2 cells, with EC50 values lower and maximum re-
sponses comparable to histamine (Table II). Long-term expo-
sure (24 h) of CHOrH2 cells to amselamine or amthamine
resulted in a dose-dependent decrease of [125I]APT binding
with EC50 values, which were correlated with their respective
EC50 values for the cAMP response. Amselamine and
amthamine induced a maximal decrease of [125I]APT binding
sites of 50 6 3% and 43 6 4% respectively. As shown in Table
II, 24-h incubation of CHOrH2 cells with 100 mM dimaprit,
which exhibits a lower potency as compared to histamine, in-
duced a 40 6 3% decrease of [125I]APT binding sites. Dimaprit’s
structural analogues, homodimaprit and nordimaprit, showed
strongly reduced capacities to generate cAMP with EC50 values
of 1.4 6 0.9 mM and higher than 10 mM, respectively (Table II).
The reduced ability of these dimaprit analogues to induce a
cAMP response was paralleled by a lack of H2 receptor down-
regulation after 24 h of incubation of CHOrH2 cells with 100 mM
concentrations of the analogues (Table II).
Effect of Long-term Histamine Treatment on Histamine- and
Forskolin-induced Signaling in CHOrH2 Cells—Long-term ex-
posure (24 h) of CHOrH2 cells with 100 mM histamine resulted
in a rightward shift of the dose-response curve of the hista-
mine-induced cAMP production (EC50 of histamine-induced
cAMP response in nontreated cells: 36 6 3 nM, mean 6 S.E., n
5 7, and histamine-treated cells: 1.2 6 0.05 mM, mean 6 S.E.,
n 5 4) (Fig. 2A). The forskolin-induced rise in cAMP was not
found to be affected as no change in dose dependence or im-
FIG. 1. Time- and dose-dependent decrease of [125I]APT bind-
ing in CHOrH2 cells by histamine. A, CHOrH2 cells were incubated
with 100 mM histamine for the indicated times, and [125I]APT binding in
membranes was measured. The [125I]APT binding is expressed as a
percentage of [125I]APT binding measured in nontreated cells. The data
shown represent the mean 6 S.E. of 4 independent experiments. B,
dose-dependent decrease of [125I]APT binding induced by histamine.
CHOrH2 cells were exposed to various concentrations of histamine for
24 h. The data represent the mean 6 S.E. of 7 independent
experiments.
TABLE I
Characteristics of the [125I]APT binding to the rat histamine H2
receptor expressed in CHO cells pretreated for 24 h with or without
histamine or forskolin
The dissociation constant (Kd) and maximum number of binding sites
(Bmax) were determined using nonlinear fitting according to a one-site
binding mode. The data shown represent the mean 6 S.E. of 3 inde-
pendent experiments.
Pretreatment (24 h)
[125I]APT binding
Kd Bmax
nM fmol/mg protein
Control 0.43 6 0.06 975 6 12
Histamine (100 mM) 0.42 6 0.05 468 6 129a
Forskolin (10 mM) 0.29 6 0.03a 324 6 59a
a Significant difference (p , 0.05) from control, represented by un-
treated cells.
TABLE II
EC50 values and the percentage of maximally induced production
(Emax) of different H2 agonists for production of cAMP and the
maximally induced effect of a 24-h incubation of these compounds on
[125I]APT binding in CHOrH2 cells
Data of the Emax values are shown as a percentage of the histamine
(100 mM)-induced cAMP response. The effect of 24 h of incubation of
CHOrH2 cells with the different compounds on [
125I]APT binding is
expressed as the percentage of H2 receptor down-regulation. The data
shown represent the mean 6 S.E. of 4 to 8 independent experiments.
cAMP response Down-regulation
EC50 % Emax EC50
% receptor
down-regulation
Histamine 66 6 29 nM 100 6 4 18 6 6 nM 41 6 6a
Amselamine 15 6 6 nM 88 6 10 5 6 1 nM 50 6 3a
Amthamine 5 6 1 nM 89 6 6 2 6 1 nM 43 6 4a
Dimaprit 0.2 6 0.07 mM 122 6 8 0.1 6 0.04 mM 40 6 3a
Nordimaprit .10 mM 70 6 3b .10 mM 7 6 9c
Homodimaprit 1.4 6 0.9 mM 38 6 1 .10 mM 11 6 5c
a Significant difference (p , 0.05) from control, represented by non-
treated cells.
b The Emax value of nordimaprit was determined using a concentra-
tion of 1 mM.
c Determined at 100 mM.
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pairment of the maximal forskolin-induced cAMP response was
observed after a 24-h pretreatment of cells with 100 mM hista-
mine (Fig. 2B).
Role of cAMP in the Process of H2 Receptor Down-regula-
tion—Forskolin, which directly activates adenylyl cyclase, dose
dependently induced the formation of cAMP in CHOrH2 cells
(Fig. 3A). Prolonged exposure (incubation periods ranging from
4 to 32 h) of CHOrH2 cells with 10 mM forskolin led to a marked
reduction of 58 6 2% [125I]APT binding (Fig. 3B). Again, no
major change in affinity of [125I]APT for the H2 receptor was
apparent, only a decrease in Bmax was observed when CHOrH2
cells were incubated for 24 h with 10 mM forskolin (Table I).
Maximum and half-maximum down-regulation was recorded
after 16 h and approximately 7 h of incubation of CHOrH2 cells
with 10 mM forskolin, respectively (Fig. 3B). The H2 receptor
binding sites appeared to be dose dependently down-regulated
by increasing concentrations of forskolin, with an EC50 value of
0.3 6 0.06 mM (mean 6 S.E., n 5 4) (Fig. 3C). Concentrations up
to 10 mM of the inactive analogue 1,9-dideoxyforskolin, which
does not generate cAMP in CHOrH2 cells (Fig. 3A), did not
attenuate the H2 receptor density after 24 h of pretreatment
(Fig. 3D).
Cholera toxin (CTX), which irreversibly activates the Gs-
protein, thereby generating cAMP, also induced a dose-depend-
ent decrease of [125I]APT binding sites when incubated for 24 h
(EC50 5 32 6 1 ng/ml, mean 6 S.E., n 5 4, Fig. 4). CTX
pretreatment of CHOrH2 cells resulted in a maximum down-
regulation of H2 receptors of 46 6 3%. Finally, exposure of
CHOrH2 cells for 24 h to 300 mM IBMX, a cAMP phosphodies-
terase inhibitor, also resulted in an attenuation of [125I]APT
binding (26 6 7% H2 receptor down-regulation, n 5 4, mean 6
S.E., p , 0.05).
H2 Receptor mRNA Levels and Stability in Control, Hista-
mine-treated, and Forskolin-treated CHOrH2 Cells—Exposure
of CHOrH2 cells to 100 mM histamine for increasing periods of
time resulted in a rapid transient decrease of H2 receptor
mRNA (maximum reduction of 71 6 4%, mean 6 S.E., n 5 4)
(Fig. 5). This effect was at its peak after 4 h of incubation of
cells with histamine (100 mM), while the amount of H2 receptor
mRNA returned to approximately 50% of control after 12 h of
histamine treatment. Long-term incubation of CHOrH2 cells
with 10 mM forskolin also induced a time-dependent transient
decrease (maximum reduction: 75 6 7%, mean 6 S.E., n 5 4) of
H2 receptor mRNA to levels similar to those observed after
histamine treatment (Fig. 5).
To study the role of mRNA stability, CHOrH2 cells were
incubated for 1 h in the absence or presence of histamine (100
mM) or forskolin (10 mM), whereafter actinomycin D (10 mg/ml)
was added to block mRNA transcription. Cells were collected at
different time intervals ranging from 0 to 90 min after addition
of actinomycin D and were analyzed for H2 receptor mRNA
content. The H2 receptor mRNA in nontreated cells was hardly
affected during the 90 min of incubation with actinomycin D
(inset, Fig. 5). Incubation of cells with 100 mM histamine, how-
ever, resulted in a significant breakdown of H2 receptor mRNA
levels (inset, Fig. 5). Similar results were obtained after for-
skolin treatment (inset, Fig. 5).
Differences between Histamine- and Forskolin-induced H2
Receptor Down-regulation—As can be seen in Fig. 5, 4 h of
incubation of cells with 100 mM histamine resulted in a marked
down-regulation (71 6 4%) of the H2 receptor mRNA, whereas
after 4 h of incubation of CHOrH2 cells and direct measure-
ment of [125I]APT binding, no significant down-regulation of H2
receptors was observed (Fig. 1A). Yet, when CHOrH2 cells were
incubated with 100 mM histamine for 1, 2, or 4 h, extensively
washed and further incubated in serum-free medium without
histamine for 23, 22, and 20 h, respectively, a significant re-
duction of H2 receptor binding sites was observed (Fig. 6A).
Interestingly, similar experiments in which CHOrH2 cells were
incubated for 1, 2, or 4 h with 10 mM forskolin followed by
extensive washing and further incubation of cells in serum-free
medium, showed a clearly delayed reduction in the number of
H2 receptor binding sites (Fig. 6A).
In order to eliminate the cAMP-dependent pathway of H2
receptor down-regulation, we incubated the CHOrH2 cells with
the protein kinase A inhibitor H-89. However, long-term expo-
sure (24 h) of CHOrH2 cells to 10 mM H-89 resulted already in
a 55 6 2% (mean 6 S.E., n 5 6) decrease of [125I]APT binding
sites. Similar data were obtained with another protein kinase A
inhibitor KT5720.2 Taking into account that H-89 itself in-
duces a reduction in [125I]APT binding sites, CHOrH2 cells
were exposed to 1 mM histamine and 1 mM forskolin in the
presence of 10 mM H-89 for 24 h. As can be seen in Fig. 6B, the
forskolin-induced effect is inhibited by co-incubation with 10
mM H-89 as no H2 receptor down-regulation is observed. Yet,
long-term incubation of cells with histamine and H-89 still
2 M. J. Smit, unpublished observations.
FIG. 2. Effect of long-term histamine treatment on histamine-
and forskolin-induced signaling in CHOrH2 cells. CHOrH2 cells
were treated with (open circles) or without (filled circles) 100 mM hista-
mine for 24 h in DMEM without fetal calf serum. Thereafter, cells were
washed several times and incubated for 1 h with DMEM supplemented
with 25 mM HEPES, pH 7.4. CHOrH2 cells were subsequently incu-
bated with increasing concentrations of histamine (A) or forskolin (B)
for 10 min at 37 °C in DMEM in the presence of 300 mM IBMX and 25
mM HEPES, pH 7.4. The data represent the mean 6 S.E. of 4 independ-
ent experiments.
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induces down-regulation, suggesting that a cAMP-independ-
ent pathway is responsible for the histamine-induced
down-regulation.
Functional Analysis of the Leu1243 Ala Mutation of the Rat
Histamine H2 Receptor—Using the polymerase chain reaction,
leucine 124 in the second intracellular loop of the rat histamine
H2 receptor (Fig. 7) was mutated into an alanine residue.
Transfection of the H2 Leu
124 3 Ala receptor cDNA into CHO
cells, resulted in the formation of several clonal cell lines ex-
pressing [125I]APT binding sites. A clonal cell line expressing
amounts of [125I]APT binding comparable to those of the
CHOrH2 cells was chosen for further analysis and referred to
as CHOrH2Leu
124Ala (CHOrH2 cells: 975 6 12 fmol/mg of
protein, CHOrH2Leu
124Ala cells: 980 6 7 fmol/mg of protein,
mean 6 S.E., n 5 3). There were no major differences in the
binding of the H2 antagonists to the wild-type receptor or the
mutated receptor. The affinity of [125I]APT for the mutated
receptor was hardly affected (Kd of [
125I]APT in CHOrH2 cells:
0.43 6 0.06 nM, in CHOrH2Leu
124Ala cells: 0.61 6 0.03 nM,
mean 6 S.E., n 5 3). Moreover, cimetidine and ranitidine had
similar Ki values for both receptors (Table III). In contrast, the
introduced Leu124 3 Ala mutation significantly affected the
agonist binding characteristics. In CHOrH2 cells, histamine
displacement curves were shallow and could be analyzed best
by a two-site model (Fig. 8, Table III). The addition of 10 mM
GTPgS resulted in a steepening and a rightward shift of the
histamine displacement curve, which could be analyzed best by
a single site model with a Ki value of 0.18 6 0.02 mM (Fig. 8).
In CHOrH2Leu
124Ala cells, however, the displacement curve of
histamine was analyzed best by a single site model, leading to
a Ki value (0.21 6 0.02 mM) that corresponded to the low
affinity site of the wild-type receptor (Fig. 8, Table III). The
addition of 10 mM GTPgS did not result in a rightward shift of
the displacement curve of histamine (Fig. 8, Table III).
Moreover, the Leu124 3 Ala mutation also affected the abil-
ity of histamine to induce the formation of cAMP in
CHOrH2Leu
124Ala cells (Fig. 9A). The EC50 value of the hista-
mine-induced cAMP response in CHOrH2Leu
124Ala cells was
approximately 162-fold higher (11 6 3 mM, mean 6 S.E., n 5 7)
than the observed EC50 value of the histamine-induced cAMP
response in CHOrH2 cells (66 6 29 nM, mean 6 S.E., n 5 6)
measured under the same conditions. The maximum hista-
FIG. 3. Forskolin- and 1,9-dideoxyforskolin-induced cAMP production and decrease of [125I]APT binding in CHOrH2 cells. A,
dose-dependent increase of the cAMP production by forskolin (filled circles) and 1,9-dideoxyforskolin (open circles). CHOrH2 cells were incubated
with the indicated drugs with increasing concentrations for 10 min at 37 °C in DMEM in the presence of 300 mM IBMX and 25 mM HEPES, pH
7.4. Data represent the mean 6 S.E. of 6 independent experiments. B, forskolin-induced decrease of [125I]APT binding in CHOrH2 cells. CHOrH2
cells were incubated with 10 mM forskolin for the indicated times, and [125I]APT binding was measured. The [125I]APT binding is expressed as a
percentage of [125I]APT binding measured in nontreated cells. C, dose-dependent decrease of [125I]APT binding in CHOrH2 cell membranes induced
by forskolin. CHOrH2 cells were exposed to various concentrations of forskolin for 24 h. The H2 receptor density was determined as described. D,
effect of 1,9 dideoxyforskolin (ddF) and forskolin (FORS) on [125I]APT binding. CHOrH2 cells were exposed to 1 and 10 mM 1,9-dideoxyforskolin
(filled bars) and forskolin (open bars), respectively, for 24 h and examined for [125I]APT binding. The asterisks indicate a significant difference (p
, 0.05) from control, represented by the [125I]APT binding measured in untreated cells. Data from B, C, and D were calculated as mean 6 S.E.
from 4 independent experiments.
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mine-induced response was also found to be affected in
CHOrH2Leu
124Ala cells (Emax in CHOrH2 cells: 40 6 4 pmol/
well, Emax in CHOrH2Leu
124Ala cells: 18 6 1 pmol/well).
Histamine-induced Down-regulation of Rat H2 Leu
1243 Ala
Receptors—Long-term exposure (24 h) of CHOrH2Leu
124Ala
cells to increasing concentrations of histamine resulted in a
dose-dependent reduction of [125I]APT binding sites (Fig. 9B).
Whereas in CHOrH2 cells an EC50 of 18 6 6 nM (mean 6 S.E.,
n 5 7) was observed for histamine, in CHOrH2Leu
124Ala cells
histamine induced down-regulation with an EC50 value of 288
6 89 nM (mean 6 S.E., n 5 4). Comparing the histamine-
induced cAMP production and H2 Leu
1243 Ala receptor down-
regulation (Fig. 9B), a discrepancy in dose relationships is
observed. Almost 40-fold higher concentrations of histamine
are required to induce cAMP production, compared to receptor
down-regulation. Pretreatment of CHOrH2Leu
124Ala cells for
24 h with 1 mM histamine resulted in a significant degree of H2
receptor down-regulation (51 6 2%, mean 6 S.E., n 5 4),
whereas no significant cAMP production was observed after 10
min of incubation (Fig. 9B). Even after 24 h of incubation of
CHOrH2Leu
124Ala cells with 1 mM histamine, no significant
increase in cAMP was observed (data not shown). Moreover,
even at 0.1 mM histamine, significant H2 receptor down-regu-
lation was observed.
In the CHOrH2Leu
124Ala cells, the maximal histamine-in-
duced down-regulation was more pronounced (68 6 4%, mean
6 S.E., n 5 4) than was observed for the CHOrH2 cells (43 6
4%, mean 6 S.E., n 5 7). The forskolin (10 mM)-induced H2
receptor down-regulation was also found to be more pro-
nounced in the CHOrH2Leu
124Ala cells (67 6 1%, mean 6 S.E.,
n 5 3) than in CHOrH2 cells (58 6 2%, mean 6 S.E., n 5 4).
FIG. 4. Effect of long-term treatment with CTX on [125I]APT
binding in CHOrH2 cells. The CHOrH2 cells were treated with in-
creasing concentrations of CTX for 24 h. [125I]APT binding is expressed
as a percentage of [125I]APT binding measured in nontreated cells
studied under the same conditions and was measured as described
earlier. The data shown represent the mean 6 S.E. of 4 independent
experiments.
FIG. 5. Histamine- and forskolin-induced modulation of H2 re-
ceptor mRNA levels. CHOrH2 cells were incubated for the indicated
times with 100 mM histamine (filled circles) or 10 mM forskolin (open
circles). Cells were harvested, and total RNA was extracted and quan-
tified by means of a RNA slot blot assay as described under “Materials
and Methods.” The results displayed are the mean 6 S.E. of two sepa-
rate experiments, performed in duplicate. Inset, effect of histamine
treatment and forskolin treatment on H2 receptor mRNA stability.
CHOrH2 cells were incubated with (open circles) or without (open
squares) 100 mM histamine or with 10 mM forskolin (filled squares) for 1
h, before actinomycin D (10 mg/ml) was added. Cells were harvested at
0, 15, 30, 60, and 90 min after the addition of actinomycin D. The data
are the mean 6 S.E. of three separate experiments, each performed in
duplicate. The asterisks indicate a significant difference (p , 0.05) from
control, represented by untreated cells.
FIG. 6. Differences between histamine- and forskolin-induced
H2 receptor down-regulation. A, effect of short-term exposure of
CHOrH2 cells to histamine and forskolin on [
125I]APT binding to
CHOrH2 membranes. CHOrH2 cells were incubated for the indicated
times, extensively washed, and incubated in serum-free medium with-
out the stimulating agent up to 24 h. For comparison, the effect of 24-h
exposure to histamine or forskolin is shown. The effect of incubation of
CHOrH2 cells with 100 mM histamine (filled bars) or 10 mM forskolin
(open bars) on [125I]APT binding is expressed as the percentage of
[125I]APT binding sites of nontreated cells. Data shown are the mean 6
S.E. from 4 experiments. The asterisks indicate a significant difference
(p , 0.05) from control, represented by nontreated cells. B, effect of the
protein kinase A inhibitor H-89 on histamine- and forskolin-induced H2
receptor down-regulation. CHOrH2 cells were incubated for 24 h with
histamine (HA) or forskolin (FORS) in the presence of H-89. The effect
of incubation of CHOrH2 cells with 10 mM H-89 and 100 mM histamine
or 10 mM forskolin on [125I]APT binding is expressed as the percentage
of [125I]APT binding sites of cells treated with 10 mM H-89 alone. Data
shown are mean 6 S.E. from 4 experiments. The asterisks indicate a
significant difference (p , 0.05) from control, represented by cells
treated with H-89.
Down-regulation of the Histamine H2 Receptor 7579
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
DISCUSSION
In the present study we have demonstrated that the rat
histamine H2 receptor density in CHO cells is reduced about
50% by long-term exposure to histamine or selective H2 ago-
nists. Long-term treatment of CHOrH2 cells with histamine
resulted in a time-dependent (t1⁄2 ' 7 h at a concentration of 100
mM) and dose-dependent (EC50 5 18 nM at 24 h of incubation)
decrease in the number of H2 receptor binding sites. Yet, incu-
bation of CHOrH2 cells with homo- and nordimaprit, two side
chain homologues of the H2 agonist dimaprit with weak H2
agonistic activity ((23), present study), did not significantly
reduce the number of H2 receptors. These findings show that
the observed H2 agonist-induced down-regulation is a H2 re-
ceptor-mediated process. Long-term exposure of CHOrH2 cells
to histamine resulting in a reduction of H2 receptor binding
sites is paralleled by a decrease of H2 receptor responsiveness,
characterized by a 34-fold shift of the histamine dose-response
curve. The observed shift cannot be ascribed to decreased
adenylyl cyclase activity as forskolin dose-response curves re-
mained unaffected after long-term histamine exposure.
As was found for the b2-adrenergic receptor (24), a cAMP-
dependent pathway can also regulate the H2 receptor density.
Forskolin, generating cAMP upon addition, time dependently
(t1⁄2 ' 7 h at a concentration of 10 mM) and dose dependently
(EC50 5 0.3 mM at 24 h of incubation) induced H2 receptor
down-regulation. CTX and IBMX, agents that also elevate in-
tracellular levels of cAMP in CHOrH2 cells, induced down-
regulation of the H2 receptor as well. Thus, the H2 receptor
does not need to be stimulated by an agonist in order to be
down-regulated. This mechanism might be involved in heter-
ologous H2 receptor down-regulation as previously shown for
other GPCRs (see Refs. 4 and 25). The time course of the
forskolin-induced decrease of H2 receptor number in CHOrH2
cells parallels the time-dependent decrease of H2 receptors
induced by histamine. For both histamine and forskolin, half-
maximal H2 receptor down-regulation is reached after approx-
imately 7 h of incubation. Moreover, the maximum decrease of
H2 receptor numbers induced by forskolin is comparable to the
maximum agonist-mediated H2 receptor down-regulation.
Agonist-induced receptor down-regulation is a commonly oc-
curring regulatory process of the large family of GPCRs (see for
reference reviews, Refs. 4 and 25). Enhanced degradation
and/or decreased synthesis of the receptor protein are thought
to contribute to receptor down-regulation (4, 25). Agonist-in-
duced down-regulation of GPCRs is often accompanied by a
decline of receptor mRNA levels, presumably contributing to
the overall reduction in receptor number and responsiveness
(26). Indeed, incubation of CHOrH2 cells with histamine or
forskolin resulted in a transient decrease of H2 receptor mRNA
levels (70% reduction) within 4 h, which was followed by a
gradual increase of H2 receptor mRNA to 50% of control mRNA
levels in the following hours. The reduced H2 receptor mRNA
levels, 50% of the control levels, at later time points are con-
sidered to represent a new steady-state level of receptor mRNA
to maintain the down-regulated state of H2 receptors. The
reduction of H2 receptor mRNA is most likely explained by
post-transcriptional events, such as receptor mRNA destabili-
zation. For example, the b2-adrenergic receptor and thrombin
receptor in DDT1MF-2 smooth muscle cells, the endothelin ETB
receptor in ROS17/2 rat osteosarcoma cells, and also for the
b2-adrenergic receptor and muscarine m1 receptor expressed
into CHW and CHO cells, respectively, the decline in receptor
mRNA has been ascribed to destabilization of the mRNA (24,
27–30). In the presence of actinomycin D, breakdown of the H2
receptor mRNA in CHOrH2 cells was stimulated significantly
upon histamine-treated and forskolin-treated compared to non-
treated cells. Recently, it was shown that a so-called Mr 5
35,000 b-adrenergic receptor mRNA-binding protein, involved
in the destabilization of b2-adrenergic receptor mRNA, also
recognizes other GPCR transcripts (29). As such, our observa-
tions of H2 receptor mRNA destabilization fit well in an appar-
FIG. 8. Binding of histamine to the wild-type and H2 Leu
124 3
Ala receptor. Displacement of binding of 0.3 nM [125I]APT by increas-
ing concentrations of histamine in the presence (open symbols) and
absence (filled symbols) of 10 mM GTPgS in CHOrH2 cells (circles) and
CHrH2Leu
124Ala cells (squares). Mean values of triplicate determina-
tions of a typical experiment out of at least three are shown.
FIG. 7. Schematic representation of the rat histamine H2 re-
ceptor. The leucine (L) at position 124, located in the second intracel-
lular loop, was mutated to an alanine (A) by site-directed mutagenesis
as described under “Materials and Methods.”
TABLE III
Pharmacological characterization of [125I]APT binding to CHOrH2
and CHOrH2Leu
124Ala cell membranes
Membranes of CHOrH2 and CHOrH2Leu
124Ala cells were incubated
with 0.3 nM [125I]APT in the presence of the indicated drugs at increas-
ing concentrations. Ki values were obtained from the respective IC50
values. Data shown are mean 6 S.E. from at least three independent
experiments. Values in parentheses indicate the relative densities of
the high/low affinity binding site.
Compounds
Ki
CHOrH2 CHOrH2Leu
124Ala
Cimetidine 804 6 53 nM 766 6 73 nM
Ranitidine 232 6 45 nM 173 6 20 nM
Histamine
Ki, high 3.5 6 1.0 mM (39 6 7%)
Ki, low 0.24 6 0.04 mM (61 6 7%) 0.21 6 0.02 mM (100%)
110 mM GTPgS 0.18 6 0.02 mM (100%) 0.23 6 0.03 mM (100%)
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ently general mechanism of b-adrenergic receptor mRNA bind-
ing protein-mediated regulation of GPCR mRNA (29, 31).
For the b2-adrenergic receptor, the most extensively studied
GPCR, receptor down-regulation is ascribed to two pathways:
an agonist-dependent, protein kinase A-independent, and a
protein kinase A-dependent process (4, 25). Evidence for a
protein kinase A-independent pathway was obtained by studies
which showed unaffected profiles of b2-adrenergic receptor
down-regulation in mutant S49 mouse lymphoma cells defec-
tive in signal transduction components (32–35). Receptor-Gs
coupling seems to be important for the process of b2-adrenergic
receptor down-regulation, since defects in this coupling intro-
duced by mutations of the receptor or Gs-protein have lead to
impaired b2-adrenergic receptor down-regulation (33–37).
Agents responsible for the elevation of intracellular levels of
cAMP, such as forskolin and IBMX, or cAMP analogues, e.g.
dibutyryl cAMP, were shown to induce b2-adrenergic receptor
down-regulation as well, providing evidence for the existence of
cAMP-dependent receptor down-regulation (24, 25, 36). In
CHW cells, the time course of the cAMP-promoted down-regu-
lation of the b2-adrenergic receptor was much slower than the
b-agonists-induced down-regulation, suggesting that distinct
pathways can lead to down-regulation of the b2-adrenergic
receptor (24). Yet, protein kinase A-dependent phosphorylation
of the b2-adrenergic receptor appears to enhance down-regula-
tion, since receptor mutants lacking protein kinase A phospho-
rylation sites showed impaired agonist-induced down-regula-
tion (24). Taken together, b2-adrenergic receptor receptor
down-regulation seems to require receptor-Gs coupling for the
initial loss of receptor binding sites, while the cAMP-dependent
decrease of receptor mRNA levels serves to maintain the down-
regulated state by establishing a new steady-state of receptor
expression (25). The underlying biochemical mechanisms re-
sponsible for each of these events is, however, unclear so far.
In our study on CHOrH2 cells, comparable time courses and a
maximum extent of histamine-induced and forskolin-induced H2
receptor down-regulation as well as H2 mRNA down-regulation
suggest the involvement of cAMP in the process of agonist-in-
duced H2 receptor down-regulation. The initial reduction of H2
receptor mRNA upon histamine or forskolin exposure can, how-
ever, not explain the 50% reduction of the H2 receptor numbers,
since relatively short (,4 h) treatments of CHOrH2 cells with
histamine or forskolin followed by a wash-out up to 24 h led to a
more pronounced H2 receptor down-regulation upon histamine
than forskolin exposure. Thus, apparently there is no direct link
between H2 receptor mRNA and H2 receptor expression. More-
over, these data are a first indication that histamine and forsko-
lin induce H2 receptor down-regulation by different mechanisms.
The existence of a cAMP-dependent and cAMP-independent
pathway was further corroborated by the fact that the protein
kinase A inhibitor H-89 (38) inhibited the forskolin-induced, but
not the histamine-induced, H2 receptor down-regulation. More-
over, recently we have shown that down-regulation of H2 recep-
tors stably expressed into human embryonal kidney cells (HEK-
293 cells) is mediated via cAMP-dependent and cAMP-
independent processes as the histamine-induced down-
regulation was found to be more pronounced than the forskolin-
induced H2 receptor down-regulation (39).
In order to assess the role of cAMP in the process of agonist-
induced H2 receptor down-regulation in CHOrH2 cells directly,
we constructed a mutant H2 receptor which showed impaired
G-protein coupling. Recently, Moro et al. (40) have shown that
hydrophobic amino acids within a highly conserved GPCR mo-
tif DRYXXV(I)XXPL (X is any amino acid and L is leucine or
other lipophilic amino acid) in the second intracellular loop are
involved in receptor-G-protein coupling (40). In the H2 receptor
protein, a DRYCAVTDPL sequence is found at an equivalent
position of the highly conserved motif (2). Substitution of the
Leu124 residue by an alanine residue had no effect on H2
receptor expression nor on H2 antagonist binding properties.
However, the mutation induced a marked impairment of the
ability of the receptor to physically couple to its G-protein as
assessed by alterations in its agonist-binding parameters (dis-
appearance high affinity binding site, no detectable GTPgS
shift). The physical uncoupling of the H2 Leu
1243 Ala mutant
was paralleled by a functional uncoupling, characterized by an
impairment of the histamine-induced cAMP production (160-
fold reduction of the EC50 value and 55% decrease of the max-
imal cAMP response). These findings are in agreement with the
functional uncoupling reported by Moro et al. (40) after muta-
tion of a hydrophobic amino acid at similar position in the
muscarine m1, m3, and b2-adrenergic receptor.
Interestingly, long-term exposure of CHOrH2Leu
124Ala cells
to 0.1 mM and 1 mM histamine, concentrations that do not elicit
FIG. 9. Effects of Leu1243 Ala mutation on histamine-induced
cAMP production and down-regulation. A, dose-dependent in-
crease of the cAMP production by histamine in CHOrH2 cells (filled
circles) and CHOrH2Leu
124Ala cells (open circles). Cells were incubated
with increasing concentrations of histamine for 10 min at 37 °C in
DMEM in the presence of 300 mM IBMX and 25 mMHEPES, pH 7.4. The
data shown represent the mean 6 S.E. for, respectively, 6 and 7 inde-
pendent experiments. B, effects of Leu1243 Ala mutation on histamine-
induced H2 receptor down-regulation (open circles) and cAMP produc-
tion (filled circles, see also above). CHOrH2Leu cells were exposed to
increasing concentrations of histamine for 24 h, and [125I]APT binding
in membranes was measured. The [125I]APT binding is expressed as a
percentage of [125I]APT binding measured in nontreated cells. The data
shown represent the mean 6 S.E. of 4 experiments. The asterisk and
number sign indicate a significant difference (p , 0.05) from control,
represented by untreated cells and basal cAMP levels respectively.
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cAMP production, resulted in a significant reduction of
[125I]APT binding sites, indicating that a cAMP-independent
pathway is involved in the observed agonist-induced H2 recep-
tor down-regulation in CHOrH2Leu
124Ala cells. Previous find-
ings in mutant S49 mouse lymphoma cells defective in signal
transduction components also showed the existence of cAMP-
independent pathways in the agonist-induced b2-adrenergic
receptor down-regulation (32–35). However, it should be noted
that the EC50 value of histamine-induced H2 receptor down-
regulation was shifted 16-fold to the right for the H2 Leu
1243
Ala receptor compared to the wild-type receptor. These data
suggest that agonist-induced H2 receptor down-regulation de-
pends on intact receptor-G-protein coupling. As already stated
earlier, previous findings for the b2-adrenergic receptor have
shown that defective receptor-Gs coupling leads to impaired
receptor down-regulation (33–37). Remarkably, both the max-
imum histamine-induced and forskolin-induced down-regula-
tion of H2 Leu
124 3 Ala receptor were found to be more pro-
nounced than for the wild-type H2 receptor, suggesting that the
mutated receptor has become more susceptible to receptor
down-regulation. Although we do not have an explanation for
this finding, we hypothesize that the Leu124 3 Ala mutation
induces a conformational change in the second intracellular
loop of the H2 receptor protein, causing an uncoupling from the
Gs-protein but also an increase of the accessibility of molecular
entities involved in receptor degradation. Recent studies with
the parathyroid hormone receptor (41) and b1-adrenergic re-
ceptor (42) support this hypothesis. Small changes in the con-
formation of intracellular receptor domains have been shown to
augment receptor internalization (41, 42). Unfortunately, no
data on receptor down-regulation are available for these mu-
tant receptors (41, 42).
In conclusion, for the first time we have demonstrated that
the histamine H2 receptor is down-regulated by prolonged
treatment with H2 agonists. Elevation of cAMP by long-term
incubation of CHOrH2 cells with forskolin, CTX, and IBMX, is
also shown to induce H2 receptor down-regulation. These data
suggest the involvement of protein kinase A in the process of
H2 receptor down-regulation and provides a mechanism for
heterologous H2 receptor regulation. Also, H2 receptor mRNA
levels were rapidly down-regulated upon both histamine treat-
ment and forskolin treatment. However, the agonist-induced
and forskolin-induced H2 receptor down-regulation do appear
to be differentially regulated, by a cAMP-dependent and cAMP-
independent pathway. Substitution of the hydrophobic amino
acid leucine 124, located within the highly conserved G-protein
coupling motif DRYXXV(I)XXPL in the second intracellular
loop of the H2 receptor, by an alanine generated a mutant
receptor with impaired ability to couple to its G-protein. Inter-
estingly, the H2 Leu
1243 Ala mutant receptor was still down-
regulated by histamine, at concentrations which showed no
increase of cAMP, thereby providing additional evidence for a
cAMP-independent pathway in the process of agonist-induced
H2 receptor down-regulation. Thus, H2 receptor down-regula-
tion appears to be induced by two distinct pathways, a cAMP-
dependent and cAMP-independent pathway.
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